LIVIVO - Search results -

Search results

Result 1 - 10 of total 24

Search options

Article: Investigation of Antibacterial and Anti-Diarrhoeal Activities of 80% Methanol Leaf and Fruit Extract of

Mengie Ayele, Teklie / Chekol Abebe, Endeshaw / Bogale Kassie, Achenef

2021 Volume 13, Page(s) 613–626

Abstract: Background: Leonotis ocymifolia: Methods: The leaves and fruits of : Results: A significant (: Conclusion: Results from this study collectively indicated that 80% methanol leaf and fruit extracts ... ...

Abstract	Background: Leonotis ocymifolia Methods: The leaves and fruits of Results: A significant ( Conclusion: Results from this study collectively indicated that 80% methanol leaf and fruit extracts of
Language	English
Publishing date	2021-06-29
Publishing country	New Zealand
Document type	Journal Article ; Retracted Publication
ZDB-ID	2587465-2
ISSN	1179-1454
ISSN	1179-1454
DOI	10.2147/JEP.S319981
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.

Chekol Abebe, Endeshaw / Yibeltal Shiferaw, Mestet / Tadele Admasu, Fitalew / Asmamaw Dejenie, Tadesse

Frontiers in immunology

2022 Volume 13, Page(s) 991092

Abstract: Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B cell malignancies, such as multiple myeloma (MM). It is a second- ... ...

Abstract	Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B cell malignancies, such as multiple myeloma (MM). It is a second-generation CAR that is outfitted with an ectodomain comprising two BCMA-binding single chain variable fragment (ScFv) domains, a transmembrane domain, and an endodomain possessing CD3ζ and 4-1BB. Cilta-cel is an autologous, gene-edited CAR T-cell that is prepared by collecting and modifying the recipient's T-cells to create a patient personalized treatment in the laboratory to be infused back. This CAR T-cell product exceptionally entails CARs with two BCMA-targeting single-domain antibodies that detect two epitopes of BCMA expressed on the malignant cells of MM. Cilta-cel is the current addition to the treatment armamentarium of relapsed or refractory (r/r) MM after its approval by the FDA on February 28, 2022, based on the results of the Phase 1b/2 CARTITUDE-1 study. It was the second approved anti-BCMA CAR T-cell product after idecabtagene vicleucel (ide-cel) to treat myeloma patients. It induces early, deep, and long-lasting responses with a tolerable safety profile in r/r MM. Cilta-cel-treated myeloma patients may potentially experience adverse effects ranging from mild to life-threatening, but they are mostly manageable toxicities. Besides, it has a consistent safety profile upon a longer follow-up of patients. Cilta-cel generally outperforms ide cel in terms of efficacy in MM, but shows comparable adverse events. This review highlights the current updates on cilta-cel efficacy, adverse events, comparison with ide-cel, and its future direction in the treatment of MM.
MeSH term(s)	B-Cell Maturation Antigen ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Epitopes/metabolism ; Humans ; Multiple Myeloma ; Receptors, Chimeric Antigen ; Single-Chain Antibodies/genetics ; Single-Chain Antibodies/metabolism ; Single-Domain Antibodies/metabolism ; T-Lymphocytes
Chemical Substances	B-Cell Maturation Antigen ; Epitopes ; Receptors, Chimeric Antigen ; Single-Chain Antibodies ; Single-Domain Antibodies ; idecabtagene vicleucel (8PX1X7UG4D)
Language	English
Publishing date	2022-09-02
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.991092
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Phytochemical Investigation and Determination of Antibacterial Activity of Solvent Leave Extracts of

Ayalew Tiruneh, Tizezew / Ayalew Tiruneh, Gebrehiwot / Chekol Abebe, Endeshaw / Mengie Ayele, Teklie

Infection and drug resistance

2022 Volume 15, Page(s) 807–819

Abstract: Background: Among many traditionally used medicinal plants, : Methods: In this study, 800 g of powdered leaves of : Results: The three extracts (methanol, ethyl acetate, and chloroform) of : Conclusion: Data obtained from this study ... ...

Abstract	Background: Among many traditionally used medicinal plants, Methods: In this study, 800 g of powdered leaves of Results: The three extracts (methanol, ethyl acetate, and chloroform) of Conclusion: Data obtained from this study collectively indicated that the three solvent extracts of
Language	English
Publishing date	2022-03-04
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2494856-1
ISSN	1178-6973
ISSN	1178-6973
DOI	10.2147/IDR.S352049
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Undernutrition and associated factors among internally displaced lactating mothers in Sekota camps, northern Ethiopia: A cross-sectional study.

Mengstie, Misganaw Asmamaw / Worke, Mulugeta Dile / Belay, Yalemshet / Chekol Abebe, Endeshaw / Asmamaw Dejenie, Tadesse / Abdu Seid, Mohammed / Azezew, Muluken Teshome

Frontiers in nutrition

2023 Volume 10, Page(s) 1108233

Abstract: Background: Undernutrition is the term used to describe when a person consumes insufficient amounts of nutrients and energy to meet their needs for maintaining health. Despite substantial progress, undernutrition remains a serious public health concern ... ...

Abstract	Background: Undernutrition is the term used to describe when a person consumes insufficient amounts of nutrients and energy to meet their needs for maintaining health. Despite substantial progress, undernutrition remains a serious public health concern in many low and middle-income nations, including Ethiopia. Women and children are, in reality, the most nutritionally vulnerable individuals, particularly in times of crisis. In Ethiopia, 27 percent of lactating women are thin or malnourished, and 38% of children are stunted. Although the issue of undernutrition may worsen in times of emergency, like war, there are limited studies available in Ethiopia that show the nutritional status of lactating mothers in humanitarian settings. Objectives: The main aim of this study was to determine the prevalence and investigate the factors associated with undernutrition among internally displaced lactating mothers in Sekota camps, in northern Ethiopia. Methods: A cross-sectional study through a simple random sampling technique was conducted among 420 randomly selected lactating mothers in Sekota Internally Displaced Persons (IDP) camps. Data were collected using a structured questionnaire and anthropometric measurements. Logistic regression analysis was employed to identify independent factors associated with maternal undernutrition. Results: Using a cut-off mid-upper arm circumference <23 cm, the prevalence of undernutrition among internally displaced lactating mothers was 54.8%. Large family size [adjusted odds ratio (AOR) = 4.35; 95% CI: 1.32, 10.22], short birth interval (AOR = 4.85; 95% CI: 1.24, 10.00), low maternal daily meal frequency (AOR = 2.54; 95% CI: 1.12, 5.75), and low dietary diversity score (AOR = 1.79; 95% CI: 1.03, 3.10) were all significantly associated with undernutrition. Conclusion: The prevalence of undernutrition among internally displaced lactating mothers is relatively high. Governments and other concerned organizations involved in providing care and support to Sekota IDP camps should increase their efforts to improve the nutritional status of lactating mothers.
Language	English
Publishing date	2023-02-14
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2776676-7
ISSN	2296-861X
ISSN	2296-861X
DOI	10.3389/fnut.2023.1108233
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study.

Jemal, Mohammed / Shibabaw Molla, Tewodros / Tiruneh G Medhin, Markeshaw / Chekol Abebe, Endeshaw / Asmamaw Dejenie, Tadesse

Annals of medicine

2023 Volume 55, Issue 2, Page(s) 2295435

Abstract: Background: Antiretroviral therapy-linked metabolic abnormalities have become a growing concern among people living with HIV. There is limited data regarding the effects of dolutegravir-based treatment on blood glucose levels and serum lipid profiles in ...

Abstract	Background: Antiretroviral therapy-linked metabolic abnormalities have become a growing concern among people living with HIV. There is limited data regarding the effects of dolutegravir-based treatment on blood glucose levels and serum lipid profiles in people living with HIV in Ethiopia. Thus, this study aimed to assess blood glucose levels and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based therapy. Method and materials: An institutional-based comparative cross-sectional study was conducted from 30 June 2021 to 30 August 2021. A total of 128 participants (64 in the dolutegravir-based group and 64 in the efavirenz-based group) were enrolled in the study. The Chi-square, independent Result: The prevalence of hyperglycemia and dyslipidemia were 17.2% (11/64) and 79.7% (51/64) in the dolutegravir group, and 9.4% (6/64) and 75% (48/64) in the efavirenz group, respectively. The efavirenz group had significantly higher mean values of total cholesterol (190.73 ± 44.13 vs. 175.27 ± 37.67 mg/dl, Conclusion: Efavirenz-based therapy resulted in higher mean values of total cholesterol and high-density lipoprotein as compared with dolutegravir-based therapy. It is important to consider and evaluate high-density lipoprotein levels in HIV patients on dolutegravir-based therapy, and total cholesterol levels in people living with HIV on efavirenz-based therapy.
MeSH term(s)	Humans ; Male ; Female ; HIV Infections/drug therapy ; Blood Glucose ; Cross-Sectional Studies ; Benzoxazines/therapeutic use ; Heterocyclic Compounds, 3-Ring/adverse effects ; Hyperglycemia ; Lipids ; Cholesterol ; Lipoproteins, HDL/therapeutic use ; Dyslipidemias/chemically induced ; Dyslipidemias/epidemiology ; Anti-HIV Agents/adverse effects
Chemical Substances	efavirenz (JE6H2O27P8) ; dolutegravir (DKO1W9H7M1) ; Blood Glucose ; Benzoxazines ; Heterocyclic Compounds, 3-Ring ; Lipids ; Cholesterol (97C5T2UQ7J) ; Lipoproteins, HDL ; Anti-HIV Agents
Language	English
Publishing date	2023-12-20
Publishing country	England
Document type	Journal Article
ZDB-ID	1004226-x
ISSN	1365-2060 ; 1651-2219 ; 0785-3890 ; 1743-1387
ISSN (online)	1365-2060 ; 1651-2219
ISSN	0785-3890 ; 1743-1387
DOI	10.1080/07853890.2023.2295435
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 680: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target.

Chekol Abebe, Endeshaw / Mengie Ayele, Teklie / Tilahun Muche, Zelalem / Asmamaw Dejenie, Tadesse

Biologics : targets & therapy

2021 Volume 15, Page(s) 143–152

Abstract: The novel coronavirus disease 2019 (COVID-19) pandemic is severely challenging the healthcare systems and economies of the world, which urgently demand vaccine and therapy development to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ...

Abstract	The novel coronavirus disease 2019 (COVID-19) pandemic is severely challenging the healthcare systems and economies of the world, which urgently demand vaccine and therapy development to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, advancing our understanding of the comprehensive entry mechanisms of SARS-CoV-2, especially the host factors that facilitate viral infection, is crucial for the discovery of effective vaccines and antiviral drugs. SARS-CoV-2 has previously been documented to reach cells by binding with ACE2 and CD147 receptors in host cells that interact with the spike (S) protein of SARS-CoV-2. A novel entry factor, called neuropilin 1(NRP1), has recently been discovered as a co-receptor facilitating the entry of SARS-CoV-2. NRP1 is a single-pass transmembrane glycoprotein widely distributed throughout the tissues of the body and acts as a multifunctional co-receptor to bind with different ligand proteins and play diverse physiological roles as well as pathological and therapeutic roles in different clinical conditions/diseases, including COVID-19. The current review, therefore, briefly provides the overview of SARS-CoV-2 entry mechanisms, the structure of NRP1, and their roles in health and various diseases, as well as extensively discusses the current understanding of the potential implication of NRP1 in SARS-CoV-2 entry and COVID-19 treatment.
Language	English
Publishing date	2021-05-06
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2415708-9
ISSN	1177-5491 ; 1177-5475
ISSN (online)	1177-5491
ISSN	1177-5475
DOI	10.2147/BTT.S307352
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Attitude and level of COVID-19 vaccination and its determinants among patients with chronic disease visiting Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia: A cross-sectional study.

Dagnew Baye, Nega / Agegnehu Teshome, Assefa / Agimas Ayenew, Atalo / Tilahun Mulu, Anmut / Chekol Abebe, Endeshaw / Tilahun Muche, Zelalem

PloS one

2022 Volume 17, Issue 12, Page(s) e0278914

Abstract: Introduction: Coronavirus disease is a fatal viral disease caused by severe acute respiratory syndrome coronavirus 2. This study was aimed to assess the attitude, level of COVID-19 vaccine uptake, and its determinants among patients with chronic ... ...

Abstract	Introduction: Coronavirus disease is a fatal viral disease caused by severe acute respiratory syndrome coronavirus 2. This study was aimed to assess the attitude, level of COVID-19 vaccine uptake, and its determinants among patients with chronic diseases visiting Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia. Methods: An institutional-based cross-sectional study was conducted among 422 randomly selected patients with chronic disease visiting Debre Tabor Comprehensive Specialized Hospital from February 1 to March 30, 2022. Bivariable and multivariable binary logistic regression analyses were done to identify associations between dependent and independent variables. Results: Among all participants, only 29.6% of patients were vaccinated with any of the COVID-19 vaccines at least one dose. Age from 31 to 40 years (AOR = 6.26, 95% CI: 2.69-14.56), attended collage and above (AOR = 6.3, 95% CI: 1.37, 28.68), positive attitude towards COVID-19 vaccine (AOR = 9.07, 95% CI: 4.51-18.22), good knowledge (AOR = 7.63, 95% CI: 1.08-16.85), history of COVID-19 (AOR = 4.33, 95% CI: 1.85-10.17), family history of COVID-19 (AOR = 3.99, 95% CI = 1.89-8.48), ever been tested for COVID-19 (AOR = 0.33, 95% CI: 0.15-0.74) were determinant factors for COVID-19 vaccine uptake. Conclusion: COVID-19 vaccine uptake among patients with chronic disease was very low. The main reasons for not being vaccinated were doubts about vaccine efficacy, the vaccine may cause disease by itself, and fear of adverse effects. Therefore, different stakeholders should enforce vaccine uptake and awareness creation.
Language	English
Publishing date	2022-12-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0278914
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Current updates on generations, approvals, and clinical trials of CAR T-cell therapy.

Asmamaw Dejenie, Tadesse / Tiruneh G/Medhin, Markeshaw / Dessie Terefe, Gashaw / Tadele Admasu, Fitalew / Wale Tesega, Wondwossen / Chekol Abebe, Endeshaw

Human vaccines & immunotherapeutics

2022 Volume 18, Issue 6, Page(s) 2114254

Abstract: Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that is considered a 'living' and self-replicating drug to treat cancer, sometimes resulting in a complete cure. CAR T-cells are manufactured through genetic engineering ... ...

Abstract	Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that is considered a 'living' and self-replicating drug to treat cancer, sometimes resulting in a complete cure. CAR T-cells are manufactured through genetic engineering of T-cells by equipping them with CARs to detect and target antigen-expressing cancer cells. CAR is designed to have an ectodomain extracellularly, a transmembrane domain spanning the cell membrane, and an endodomain intracellularly. Since its first discovery, the CAR structure has evolved greatly, from the first generation to the fifth generation, to offer new therapeutic alternatives for cancer patients. This treatment has achieved long-term and curative therapeutic efficacy in multiple blood malignancies that nowadays profoundly change the treatment landscape of lymphoma, leukemia, and multiple myeloma. But CART-cell therapy is associated with several hurdles, such as limited therapeutic efficacy, little effect on solid tumors, adverse effects, expensive cost, and feasibility issues, hindering its broader implications.
Language	English
Publishing date	2022-09-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	2664176-8
ISSN	2164-554X ; 2164-5515
ISSN (online)	2164-554X
ISSN	2164-5515
DOI	10.1080/21645515.2022.2114254
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6967: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review.

Mengie Ayele, Teklie / Tilahun Muche, Zelalem / Behaile Teklemariam, Awgichew / Bogale Kassie, Achenef / Chekol Abebe, Endeshaw

Journal of inflammation research

2022 Volume 15, Page(s) 1349–1364

Abstract: Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway is a common signaling pathway used to transduce signals from the extracellular to the intracellular (nucleus) upon the binding of cytokines and growth factors to the ... ...

Abstract	Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway is a common signaling pathway used to transduce signals from the extracellular to the intracellular (nucleus) upon the binding of cytokines and growth factors to the extracellular domain of specific cell surface receptors. This signaling pathway is tightly regulated and has a multitude of biological functions such as cell proliferation, differentiation, and apoptosis. Besides, the regulated JAK2/STAT3 signaling plays a crucial role in embryonic development, hemopoiesis, and controlling the immune system. Conversely, aberrantly activated JAK2/STAT3 is frequently detected in varieties of tumors and involved in oncogenesis, angiogenesis, and metastasis of many cancer diseases that are usually refractory to the standard chemotherapy. However, the JAK3/STAT3 pathway recently emerged interestingly as a new site for the development of novel anti-tumor agents and becomes a promising therapeutic target in the treatment of many solid malignancies. Herein, this review aimed to provide insight into the JAK2/STAT3 pathway, in the hope to gain an understanding of its potential role in the pathogenesis, progression, chemotherapy resistance, and cancer therapy of solid tumors.
Language	English
Publishing date	2022-02-25
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2494878-0
ISSN	1178-7031
ISSN	1178-7031
DOI	10.2147/JIR.S353489
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer.

Tiruneh G/Medhin, Markeshaw / Chekol Abebe, Endeshaw / Sisay, Tekeba / Berhane, Nega / Bekele, Tesfahun / Asmamaw Dejenie, Tadesse

Biologics : targets & therapy

2021 Volume 15, Page(s) 199–204

Abstract: Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins are referred to as CRISPR-Cas9. Bacteria and archaea have an adaptive (acquired) immune system. As a result, developing the best single regulated RNA and Cas9 ... ...

Abstract	Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins are referred to as CRISPR-Cas9. Bacteria and archaea have an adaptive (acquired) immune system. As a result, developing the best single regulated RNA and Cas9 endonuclease proteins and implementing the method in clinical practice would aid in the treatment of diseases of various origins, including lung cancers. This seminar aims to provide an overview of CRISPR-Cas9 technology, as well as current and potential applications and perspectives for the method, as well as its mechanism of action in lung cancer therapy. This technology can be used to treat lung cancer in two different ways. The first approach involves creating single directed RNA and Cas9 proteins and then distributing them to cancer cells using suitable methods. Single directed RNA looks directly at the lung's mutated epidermal growth factor receptor and makes a complementary match, which is then cleaved with Cas9 protein, slowing cancer progression. The second method is to manipulate the expression of ligand-receptors on immune lymphocytic cells. For example, if the CRISPR-Cas9 system disables the expression of cancer receptors on lymphocytes, it decreases the contact between the tumor cell and its ligand-receptor, thus slowing cancer progression.
Language	English
Publishing date	2021-05-31
Publishing country	New Zealand
Document type	Journal Article ; Review
ISSN	1177-5475
ISSN	1177-5475
DOI	10.2147/BTT.S310312
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED